NYSE:ENZ Enzo Biochem (ENZ) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ENZ Stock Alerts $1.13 -0.04 (-3.42%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.12▼$1.1850-Day Range$1.03▼$1.2852-Week Range$0.99▼$2.23Volume76,096 shsAverage Volume125,293 shsMarket Capitalization$57.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Enzo Biochem alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Enzo Biochem Stock (NYSE:ENZ)Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.Read More ENZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENZ Stock News HeadlinesMay 19, 2024 | finance.yahoo.comEnzo Biochem, Inc. (ENZ)March 28, 2024 | finanznachrichten.deIn Vitro Diagnostics Market Worth $119.4 billion | MarketsandMarketsMarch 14, 2024 | finanznachrichten.deEnzo Biochem, Inc.: Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateMarch 14, 2024 | finance.yahoo.comEnzo Biochem (NYSE:ENZ) shareholders have endured a 69% loss from investing in the stock three years agoMarch 13, 2024 | finance.yahoo.comEnzo Biochem: Fiscal Q2 Earnings SnapshotMarch 13, 2024 | globenewswire.comEnzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateFebruary 16, 2024 | money.usnews.comEnzo Biochem, Inc.February 14, 2024 | finance.yahoo.comJim Simons Trims Stake in Enzo Biochem IncFebruary 2, 2024 | msn.comEnzo Biochem Shareholders Elect Directors, Reject Exec PayFebruary 2, 2024 | msn.comEnzo Biochem Appoints New CEO and CFOFebruary 1, 2024 | finance.yahoo.comEnzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer AppointmentsJanuary 30, 2024 | finance.yahoo.comHere’s Why Laughing Water Capital Sold Enzo Biochem Inc (ENZ)December 16, 2023 | investorplace.comENZ Stock Earnings: Enzo Biochem Reported Results for Q1 2024December 15, 2023 | finance.yahoo.comENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATEDecember 14, 2023 | finance.yahoo.comEnzo Biochem Inc (EZB.SG)December 13, 2023 | finance.yahoo.comImmunoassay Market is Expected to Reach $46.7 Billion | MarketsandMarkets.November 19, 2023 | morningstar.comEnzo Biochem Inc ENZNovember 8, 2023 | finance.yahoo.comGlobal Oxidative Stress Assays Market to Reach $1.9 Billion by 2030: Players Include Cell Biolabs, Enzo Biochem, Merck and MilliporeSigmaOctober 30, 2023 | finance.yahoo.comSteven J. Pully Appointed to Enzo Biochem’s Board of DirectorsOctober 30, 2023 | benzinga.comPoint of Care Molecular Diagnostics Market Worth $5.38 Billion by 2028 - Exclusive Report by The Insight PartnersOctober 26, 2023 | msn.comEnzo Biochem: Cleaned Up And Cash-Rich But UnlovedOctober 23, 2023 | finance.yahoo.comEsoteric Testing Market to grow by USD 18.87 billion from 2022-2027, North America to account for 36% of market growth - TechnavioOctober 6, 2023 | finance.yahoo.comEnzo Biochem (NYSE:ENZ) shareholders have endured a 63% loss from investing in the stock five years agoSeptember 18, 2023 | finance.yahoo.comNeurological Biomarkers Market to grow by USD 6.92 billion from 2022 to 2027 | North America to account for 43% of market growth- TechnavioSeptember 11, 2023 | finance.yahoo.comNeuroscience Antibodies and Assays Market to grow by USD 1.83 billion from 2022 to 2027, North America to account for 46% of market growth- TechnavioSee More Headlines Receive ENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/15/2019Today6/08/2024Next Earnings (Estimated)6/12/2024Fiscal Year End7/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNYSE:ENZ CUSIPN/A CIK316253 Webwww.enzo.com Phone(212) 583-0100Fax212-679-7999Employees179Year Founded1976Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$20.29 million Net Margins99.28% Pretax Margin-71.07% Return on Equity-36.71% Return on Assets-22.29% Debt Debt-to-Equity RatioN/A Current Ratio3.20 Quick Ratio2.89 Sales & Book Value Annual Sales$31.06 million Price / Sales1.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book0.72Miscellaneous Outstanding Shares51,230,000Free Float43,286,000Market Cap$57.89 million OptionableOptionable Beta0.78 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Kara Cannon (Age 55)CEO & Director Comp: $990.78kMs. Patricia Eckert CPA (Age 46)Chief Financial Officer Comp: $400.06kKey CompetitorsBiodesixNASDAQ:BDSXBurning Rock BiotechNASDAQ:BNRPersonalisNASDAQ:PSNLExagenNASDAQ:XGNRenalytixNASDAQ:RNLXView All CompetitorsInstitutional OwnershipAssenagon Asset Management S.A.Sold 52,643 shares on 4/24/2024Ownership: 0.039%View All Institutional Transactions ENZ Stock Analysis - Frequently Asked Questions How have ENZ shares performed in 2024? Enzo Biochem's stock was trading at $1.39 at the beginning of the year. Since then, ENZ stock has decreased by 18.7% and is now trading at $1.13. View the best growth stocks for 2024 here. Are investors shorting Enzo Biochem? Enzo Biochem saw a drop in short interest in April. As of April 30th, there was short interest totaling 676,700 shares, a drop of 7.2% from the April 15th total of 729,200 shares. Based on an average daily trading volume, of 113,100 shares, the short-interest ratio is presently 6.0 days. Approximately 1.9% of the shares of the stock are short sold. View Enzo Biochem's Short Interest. When is Enzo Biochem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our ENZ earnings forecast. How were Enzo Biochem's earnings last quarter? Enzo Biochem, Inc. (NYSE:ENZ) posted its quarterly earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. The medical research company had revenue of $20.92 million for the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 36.71% and a net margin of 99.28%. What other stocks do shareholders of Enzo Biochem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU). Who are Enzo Biochem's major shareholders? Enzo Biochem's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.04%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Hamid Erfanian, James G Wolf and Kara Cannon. View institutional ownership trends. How do I buy shares of Enzo Biochem? Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENZ) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzo Biochem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enzo Biochem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.